James Foelsch, MD
Neurology · Fairbanks, AKNPI 1447219589
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for neurology clinicians in AK, where the typical reported total is $2,594.
Across 90 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$534
- AbbVie$274
- Novartis$202
- Neurocrine Biosciences, Inc.$190
- Teva Pharmaceuticals USA, Inc.$147
- Takeda Pharmaceuticals U.S.A., Inc.$125
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$281%
- Food & beverage$2,48198%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 15 | $534 |
| AbbVie(2 entities) | 11 | $274 |
| Novartis | 8 | $202 |
| Neurocrine Biosciences, Inc. | 7 | $190 |
| Teva Pharmaceuticals USA, Inc. | 7 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $125 |
| Bristol Myers Squibb | 5 | $120 |
| UCB, Inc. | 3 | $111 |
| Greenwich Biosciences, Inc. | 3 | $104 |
| AstraZeneca | 4 | $103 |
| Genentech USA, Inc. | 3 | $77 |
| Eisai Inc. | 3 | $72 |
| Alkermes, Inc. | 2 | $57 |
| Akcea Therapeutics, Inc. | 1 | $55 |
| Amylyx Pharmaceuticals, Inc. | 2 | $55 |
| Lundbeck LLC | 2 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $51 |
| Axsome Therapeutics, Inc. | 1 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $39 |
| Tanabe Pharma America, Inc. | 1 | $30 |
| Acorda Therapeutics, Inc | 1 | $28 |
| Argenx US, Inc. | 1 | $27 |
| Sanofi | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mavenclad$120
How this compares
$2,541 in reported general payments places this provider in the 45th percentile of 21 neurology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Fairbanks
- Ronald MartinoFairbanks$4K
- Janice OnoratoFairbanks$0
- Kristen JessenSoldotna$51K
- Stanford DownsAnchorage$19K
- Mary DownsAnchorage$17K
- John KellyWasilla$13K
- Peter OsterbauerEagle River$12K
- Jeffrey SponslerWasilla$8K
- Scot HinesAnchorage$8K
- David HenzlerAnchorage$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.